数据日期 2026-10-29 · 生成时间 2026-10-29 06:03
研究问题
Senescence was initially described as a series of cellular alterations associated with aging.
方法
Dox (Merck KGaA, Darmstat, Germany) was added at 2.5 µg/mL.；Infected cells were selected with 10 µg/mL puromycin (Merck KGaA, Darmstat, Germany) 24 h after infection.；For replicable induction of senescence in T47D cells, the following treatment conditions were established: 0.05 μM doxorubicin (DR or DoxoR), 0.5 μM alisertib (AL) and 0.5 μM etoposide (ET) for 5 days.；RNA Extraction and Reverse Transcri] Senescent cells were prepared by seeding 0.5 × 106 cells in seven ∅ 10 cm dishes and treated with the drugs as described previously (dishes: 2× AL, 2× ET, 2× DR, 1× Control).
核心结论
The drug concentrations and conditions that gave more senescence induction with reduced cell lethality were chosen: 0.05 μM doxorubicin (DR or DoxoR), 0.5 μM alisertib (AL) and 0.5 μM etoposide (ET) for 5 days. ‖ 结论：Together, these depletion models suggest that maintaining optimal H1 variant stoichiometry may be required to prevent spontaneous senescence, whereas global H1 depletion via CRAMP1 loss may cause p21-mediated cell cycle arrest and innate immune signaling.
局限
全文未设独立 limitations 节；结构上为非 RCT 设计，因果推断强度受限。
对本项目的价值
★★★☆☆ 细胞衰老清除/重编程是项目干预管线的核心支柱之一。命中核心 细胞衰老。
全文来源
PMC JATS 全文（正文 42,311 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：Dynamic Changes of Histone H1 Variants in Drug-Induced Senescence.
- 期刊与标识：Genes (Basel) · PMID 42938390 · DOI 10.3390/genes17101274**
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。